Skip to main content

Table 1 Baseline characteristics of patients in the erenumab clinical trials [23, 24, 28]

From: Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials

Characteristic

Episodic migraine

(NCT02456740)

STRIVE

Episodic migraine

(NCT02483585)

ARISE

Chronic migraine

(NCT02066415)

Placebo

Erenumab

70 mg

Erenumab

140 mg

Placebo

Erenumab

70 mg

Placebo

Erenumab

70 mg

Erenumab

140 mg

Number of patients

319

317

319

291

286

286

191

190

Mean age, years (SD)

41.3 (11.2)

41.1 (11.3)

40.4 (11.1)

42.2 (11.5)

42.3 (11.4)

42.1 (11.3)

41.4 (11.3)

42.9 (11.1)

Sex, n (%)

 Male

45 (14.1)

48 (15.2)

47 (14.7)

44 (15.1)

41 (14.3)

60 (21.0)

25 (13.1)

30 (15.8)

 Female

274 (85.9)

269 (84.8)

272 (85.3)

247 (84.9)

245 (85.7)

226 (79.0)

166 (86.9)

160 (84.2)

Race, n (%)

 White

276 (86.8)

280 (88.6)

293 (91.9)

259 (89.0)

259 (90.6)

268 (93.7)

176 (92.1)

184 (96.8)

 Black

24 (7.5)

24 (7.6)

18 (5.6)

27 (9.3)

24 (8.4)

11 (3.8)

10 (5.2)

6 (3.2)

 Other

18 (5.7)

12 (3.8)

8 (2.5)

5 (1.7)

3 (1.0)

7 (2.5)

5 (2.6)

0 (0.0)

MMD

8.2 ± 2.5

8.3 ± 2.5

8.3 ± 2.5

8.4 ± 2.6

8.1 ± 2.7

18.2 ± 4.7

17.9 ± 4.4

17.8 ± 4.7

  1. Abbreviations: ARISE A phase 3, Randomised, double-blind, placebo-controlled Study to Evaluate the efficacy and safety of AMG 334 in migraine prevention, MMD monthly migraine day, SD standard deviation, STRIVE Study to evaluate the efficacy and safety of erenumab in migraine prevention